U.S. Justice Department headquarters in Washington.

The war of words over the Medicare Drug Price Negotiation Program under the Inflation Reduction Act is heating up weeks before the federal government is expected to name the first 10 drugs chosen for price negotiation for 2026.

The U.S. Chamber of Commerce, one of the largest lobbying groups in the country, filed a motion in July for a preliminary injunction against the program, claiming it would inflict "irreparable harm" on U.S. businesses and patients. The chamber claimed that the negotiations provision violates constitutional protections for free enterprise. "Instead, the IRA is custom-built to eliminate political and legal accountability for HHS decision-making and to maximize the agency's unfettered and unchecked power," the complaint said.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Core and Group Health
Health Care Reform
Employee-Paid
Employer-Paid